0001209191-19-012643.txt : 20190222
0001209191-19-012643.hdr.sgml : 20190222
20190222165120
ACCESSION NUMBER: 0001209191-19-012643
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190220
FILED AS OF DATE: 20190222
DATE AS OF CHANGE: 20190222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilbert Halley E
CENTRAL INDEX KEY: 0001601360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 19626372
MAIL ADDRESS:
STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC.
STREET 2: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-20
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001601360
Gilbert Halley E
C/O IRONWOOD PHARMACEUTICALS, INC.
301 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Legal Officer
Class A Common Stock
2019-02-20
4
S
0
2143
14.31
D
233229
D
Class A Common Stock
2019-02-20
4
S
0
2423
14.31
D
230806
D
Class A Common Stock
2019-02-20
4
S
0
2982
14.31
D
227824
D
Class A Common Stock
2019-02-20
4
S
0
2609
14.31
D
225215
D
Class A Common Stock
2019-02-21
4
S
0
18
14.32
D
225197
D
Class A Common Stock
2019-02-21
4
S
0
20
14.32
D
225177
D
Class A Common Stock
2019-02-21
4
S
0
25
14.32
D
225152
D
Class A Common Stock
2019-02-21
4
S
0
22
14.32
D
225130
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Conor Kilroy, Attorney-in-Fact
2019-02-22